Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AbbVie easily beat Wall Street estimates for the second quarter. The company also raised its full-year earnings guidance.

Why AbbVie Stock Is Jumping Today

Revenue for blockbuster arthritis drug declined in the second quarter, largely due to discounts for middlemen.

How AbbVie's Humira Still Reigns, Despite New Competition

While the top- and bottom-line numbers for AbbVie (ABBV) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Compared to Estimates, AbbVie (ABBV) Q2 Earnings: A Look at Key Metrics

On July 27, 2023, AbbVie Inc ( ABBV , Financial) experienced a day's change of 5.13%, with an Earnings Per Share (EPS) (EPS) of 4.23. The question at hand is: Is this stock modestly overvalued?

Is AbbVie Inc (ABBV) Modestly Overvalued? An In-depth Valuation Analysis

AbbVie (ABBV) came out with quarterly earnings of $2.91 per share, beating the Zacks Consensus Estimate of $2.79 per share. This compares to earnings of $3.37 per share a year ago.

AbbVie (ABBV) Beats Q2 Earnings and Revenue Estimates

Drug maker AbbVie reported Q2 profit and sales that fell from a year earlier but topped expectations. AbbVie stock rose.

AbbVie Earnings, Revenue Fall Less Than Expected

AbbVie Inc. ABBV, +0.19% shares gained 1.5% premarket on Thursday after the pharmaceutical giant reported stronger-than-expected revenue for the second quarter and raised its full-year guidance. The company now expects full-year 2023 adjusted earnings per share in the range of $10.90 to $11.10, versus previous guidance of $10.57 to $10.97.

AbbVie shares climb after quarterly results beat expectations

AbbVie on Thursday raised its annual profit forecast after beating analysts' estimates for second-quarter earnings on a lower-than-expected fall in sales of blockbuster arthritis drug Humira and strong sales of newer treatments.

AbbVie raises annual profit forecast as Humira stays strong, new drugs impress

Reports Second-Quarter Diluted EPS of $1.14 on a GAAP Basis, an Increase of 123.5 Percent; Adjusted Diluted EPS of $2.91, a Decrease of 13.6 Percent; These Results Include an Unfavorable Impact of $0.15 Per Share Related to Acquired IPR&D and Milestones Expense Delivers Second-Quarter Net Revenues of $13.865 Billion, a Decrease of 4.9 Percent on a Reported Basis and 4.2 Percent on an Operational Basis Second -Quarter Global Net Revenues from the Immunology Portfolio Were $6.813 Billion, a Decrease of 5.5 Percent on a Reported Basis, or 5.0 Percent on an Operational Basis; Global Humira Net Revenues Were $4.012 Billion; Global Skyrizi Net Revenues Were $1.883 Billion; Global Rinvoq Net Revenues Were $918 Million Second -Quarter Global Net Revenues from the Hematologic Oncology Portfolio Were $1.478 Billion, a Decrease of 10.4 Percent on a Reported Basis, or 9.8 Percent on an Operational Basis; Global Imbruvica Net Revenues Were $907 Million; Global Venclexta Net Revenues Were $571 Million Second -Quarter Global Net Revenues from the Neuroscience Portfolio Were $1.885 Billion, an Increase of 13.6 Percent on a Reported Basis, or 14.2 Percent on an Operational Basis; Global Botox Therapeutic Net Revenues Were $748 Million; Global Vraylar Net Revenues Were $658 Million Second -Quarter Global Net Revenues from the Aesthetics Portfolio Were $1.384 Billion, an Increase of 1.0 Percent on a Reported Basis, or 2.9 Percent on an Operational Basis; Global Botox Cosmetic Net Revenues Were $685 Million; Global Juvederm Net Revenues Were $368 Million Raises 2023 Adjusted Diluted EPS Guidance Range from $10.57 - $10.97 to $10.90 - $11.10, which Includes an Unfavorable Impact of $0.23 Per Share Related to Acquired IPR&D and Milestones Expense Incurred Year-To-Date Through the Second Quarter 2023 NORTH CHICAGO, Ill. , July 27, 2023 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the second quarter ended June 30, 2023.

AbbVie Reports Second-Quarter 2023 Financial Results

Citigroup

Chevron

Kraft Heinz

Altria

Pfizer

Verizon

For investors, 2022 was a dreadful year. The S&P 500 was down almost 20% and the Nasdaq lower by a stunning 33%.

Top JP Morgan Strategist Says the Worst May Still Be Coming: 7 Big-Dividend Blue Chips to Buy Now

AbbVie Inc is likely to beat Wall Street sales estimates for Humira in the second quarter as the only copycat in the U.S. market for the blockbuster arthritis drug struggled to gain traction.

AbbVie may see less pain from Humira sales decline as rival lags

AbbVie and Calibr Expand Strategic Collaboration to Advance Several Preclinical and Early-stage Clinical Assets

An open-label, efficacy assessor-blinded study comparing SKYRIZI® (risankizumab) to Otezla® (apremilast) for the treatment of adult patients with moderate plaque psoriasis who were candidates for systemic therapy was published in the British Journal of Dermatology1 Significantly more patients in the study achieved co-primary endpoints of PASI 90 and sPGA 0/1 at Week 16 with risankizumab versus apremilast1 In apremilast patients not achieving PASI 75 at Week 16, significantly more achieved the primary endpoint of PASI 90 at Week 52 who were re-randomized to risankizumab versus continued with apremilast1 Based on TSQM-9, higher treatment satisfaction domain scores were reported at Week 16 for patients taking risankizumab (nominal p-values versus apremilast)1 Risankizumab was well-tolerated with no new safety signals identified1 NORTH CHICAGO, Ill. , July 26, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the British Journal of Dermatology published results from the head-to-head Phase 4 IMMpulse study that evaluated the efficacy and safety of SKYRIZI® (risankizumab) compared to Otezla® (apremilast) among adult patients with moderate plaque psoriasis eligible for systemic therapy.1 This study achieved all primary and ranked secondary endpoints with no new safety signals identified.1 "This study highlights the efficacy of SKYRIZI compared to Otezla in helping systemic-eligible patients achieve high levels of skin clearance and reinforces the safety profile observed in previous studies," said Mudra Kapoor, M.D.

SKYRIZI® (risankizumab) Achieved Superiority Versus Apremilast for Co-Primary Endpoints Among Adult Patients with Moderate Plaque Psoriasis in Phase 4 Head-to-Head Study

Elevance Health Inc

AbbVie possesses the pharmaceutical portfolio and pipeline necessary to keep growing. Elevance Health can deliver above-average growth moving forward.

Looking to Get Richer? These 2 Dividend Stocks Have Doubled in 5 Years

In its Q2 earnings results, AbbVie's (ABBV) Skyrizi and Rinvoq sales are expected to have made up for the declining Humira sales following the loss of U.S. exclusivity.

Will AbbVie's (ABBV) New Drugs Make Up for Low Humira Sales?

Comcast

Valero Energy

After U.S. markets closed on Monday, Cadence Design beat consensus estimates on both the top and bottom lines.

Earnings Previews: AbbVie, Comcast, Valero Energy

As AbbVie Inc. ABBV, -0.63% looks to plug holes in the sales of its mega-blockbuster arthritis drug Humira, newer immunology drugs will be key to the pharmaceutical giant's future growth, analysts say.

AbbVie turns to newer immunology drugs as blockbuster Humira faces lower-cost competition

Cheaper versions of one of the most costly and widely used arthritis treatments in the U.S. are likely to fuel further scrutiny of the middlemen that negotiate drug prices for most insured Americans from lawmakers and the federal government, according to healthcare experts.

Analysis: Launch of arthritis drug biosimilars ramps up US pressure on pricing 'middlemen'

B2Gold

Novartis

Park Electrochemical

Tyson Foods

Although the best dividend stocks for portfolio protection might come off as a rather boring endeavor, at the present juncture, there may be no more relevant idea for investors. Frankly, with the world seemingly poised for a massive conflict, market participants may want to seek the relative stability of dividend investing in proven enterprises.

The 7 Best Dividend Stocks to Protect Your Portfolio From Global Chaos

Chipotle

Visa

While many remain focused on tech, there are several other notable quarterly reports scheduled to come this week, including these three.

3 Non-Tech Reports to Watch This Week

-  First registered, randomized Phase 3 trial in hidradenitis suppurativa (HS) evaluating the efficacy and safety of upadacitinib (RINVOQ ® ) in adults and adolescents with moderate to severe HS1 -   HS is a difficult-to-treat chronic, inflammatory disease with few therapeutic options available2,3 -  AbbVie applies proven expertise in immunology and HS in continued efforts to bring new treatment options to patients living with this underserved condition 4   NORTH CHICAGO, Ill. , July 24, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the first patient has been dosed in the Phase 3 Step-Up HS study evaluating upadacitinib (RINVOQ®) in adults and adolescents with moderate to severe hidradenitis suppurativa (HS) who have failed anti-tumor necrosis factor (TNF) therapy and/or one approved non-anti-TNF inhibitor therapy for HS.1 "Hidradenitis suppurativa is a chronic, inflammatory disease that often leads to irreversible skin damage and extreme pain for patients," said Roopal Thakkar, M.D.

AbbVie Advances Immunology Pipeline with First Patient Dosed in Global Phase 3 Trial of Upadacitinib (RINVOQ®) in Hidradenitis Suppurativa

Brookfield Renewable Partners

Brookfield Infrastructure Partners L.P.

AbbVie is a Dividend King with a long history of innovation. Brookfield Renewable has a clear path to long-term growth.

3 High-Yield Dividend Stocks I Plan on Holding Forever

If approved, epcoritamab (TEPKINLY®) will become the first and only subcutaneous bispecific antibody conditionally approved as a monotherapy for the treatment of adult patients with relapsed or refractory (R/R) DLBCL after two or more lines of systemic therapy The positive CHMP opinion is supported by results from the EPCORE™ NHL-1 Phase 1/2 trial evaluating the preliminary efficacy and safety of epcoritamab in patients with non-Hodgkin's lymphoma (NHL), including DLBCL DLBCL is an aggressive subtype of NHL and accounts for approximately 30 percent of all global cases NORTH CHICAGO, Ill. , July 21, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of conditional marketing authorization for epcoritamab (TEPKINLY®) as a monotherapy for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.

AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Johnson & Johnson

Coca-Cola

Investors seeking income from dividend stocks should carefully consider the yield offered. While the average yield in the S&P 500 is 1.56%, some stocks offer double or even triple that amount.

3 of the Best Dividend Stocks to Buy for Passive Income Growth

Amazon

MGM Resorts

Microsoft

NextEra Energy

ServiceNow

Tesla

Investing is about building a stable long-term portfolio, not just seeking immediate gains. In a mixed economic climate with rising employment figures, savvy investors seek forever stocks.

News for AbbVie Stock (ABBV)